Moss, 29 April 2024
The board of directors today appointed Mr. Njaal Kind as acting CEO of Gentian Diagnostics ASA. Mr. Kind joined Gentian in January 2018 as CFO. More recently he has been promoted to CFO/COO. During these years at Gentian, Mr. Kind has significantly contributed to the outstanding financial performance of the company. As acting CEO, Mr. Kind will also continue to serve as CFO and COO.
The company’s general meeting has resolved to elect Ms. Hilja Ibert as chairperson of the board of directors. Ms. Ibert has therefore resigned as CEO effective today.
“It has been a pleasure to serve Gentian Diagnostics as CEO since July 2018. I am impressed what the Gentian team has achieved during that period, in which sales has resulted in a compounded annual growth rate of 30%. With my transition to a board position, I am still committed to securing further profitable growth and development of the company. Gentian is now in safe hands with Njaal Kind as acting CEO. He is known and trusted by our stakeholders, and I am confident that he will solve this mission in an excellent manner.”
IR contact:
Njaal Kind, CEO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act